Keith Speights is a Contributing Writer and Analyst at The Motley Fool. With a diverse background in healthcare technology and finance, he covers a range of topics including personal finance, trading, economic policy, and the global economy. His insights have been featured in notable publications such as USA TODAY, Yahoo Finance, and Nasdaq.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Keith Speights focuses on investment analysis, particularly in the stock market and personal finance, with a heavy emphasis on healthcare and pharmaceuticals. He cites data significantly in his articles.
When reaching out to Keith, consider offering insights or analyses related to investing strategies, dividend stocks, social security issues, retirement planning tips or developments in the healthcare and pharmaceutical sectors. Additionally, providing data-driven perspectives would likely resonate well with him given his frequent citation of data in his coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Should you put your hard-earned money into marijuana stocks? We detail the investment opportunities, risks, and regulations in the cannabis space.
By: Keith Speights
Key Points Novartis recently announced bad news for its Lp(a)-lowering drug, pelacarsen. Lilly is also developing a therapy for lowering Lp(a).
By: Keith Speights
Analysts think Alnylam could rebound strongly over the next 12 months. There's no way to spin Alnylam Pharmaceuticals ALNY stock performance in 2026 in a positive light.
By: Keith Speights
Key Points Analysts remain bullish about Alnylam despite its steep sell-off. The competitive landscape for Alnylam is more promising now thanks to two recent developments.
By: Keith Speights
Investors should brace for short-term volatility if the Fed increases rates. Over three years.
By: Keith Speights
Key Points The S&P 500 typically declines during the first three months of a new rate-hike cycle. However, the S&P has historically risen over the next year.
By: Keith Speights
Income investors shouldn't be too worried about the pharma giant cutting its dividend.
Key Points Pfizer's management remains firmly committed to maintaining the dividend. The company's growth portfolio is performing well.
By: Keith Speights
BioNTech's recent pipeline setback is a real cause of concern. But investors shouldn't panic.
By: Keith Speights
Key Points BioNTech terminated a Phase 2 study of autogene cevumeran in treating colorectal cancer.
